Factors Influencing the Response Rate and Survival of Testicular Germ Cell Tumors: A Single Institution Experience from Egypt

H. H. Zawam, Ahmed Selim, N. Osman, W. Edesa
{"title":"Factors Influencing the Response Rate and Survival of Testicular Germ Cell Tumors: A Single Institution Experience from Egypt","authors":"H. H. Zawam, Ahmed Selim, N. Osman, W. Edesa","doi":"10.21608/resoncol.2021.79122.1146","DOIUrl":null,"url":null,"abstract":"Background: Testicular germ cell tumors (TGCTs) are the most common cancer in young adult males, and they represent one of the most curable solid tumors. The treatment modalities of different stages are variable among centers. Aim: To describe the management of TGCTs and its outcome in an Egyptian cancer center. Methods: The medical records of patients with TGCT treated between January 2012 and December 2016 were retrospectively reviewed. Thirty-two patients were included. Demographic, clinical, treatment, and outcome data were analyzed. Results: The median age of the patients was 34.5 years. The most common presentation was unilateral painless testicular mass (87.5%). Seminoma represented 53% of cases and almost half of them had Stage I disease. For all patients, the clinical stage and International Germ Cell Cancer Collaborative Group (IGCCC) risk classification were significantly associated with survival outcomes. Five-year overall survival for stage I patients was 100%, compared to 87.5% for stage II (p<0.0001). Patients with good risk had a 5-year OS of 87.4% while none of the poor risk group survived for 5 years (p =0.002). The 5-year disease-free survival for stage I was 83% for those who remained under active surveillance versus 87.5% for those who received adjuvant carboplatin (p=0.364). Conclusions: Stage I TGCTs has an excellent overall survival regardless of the treatment modality received. In advanced disease, the clinical stage and IGCCC risk stratification remain valid prognostic risk factors.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21608/resoncol.2021.79122.1146","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Background: Testicular germ cell tumors (TGCTs) are the most common cancer in young adult males, and they represent one of the most curable solid tumors. The treatment modalities of different stages are variable among centers. Aim: To describe the management of TGCTs and its outcome in an Egyptian cancer center. Methods: The medical records of patients with TGCT treated between January 2012 and December 2016 were retrospectively reviewed. Thirty-two patients were included. Demographic, clinical, treatment, and outcome data were analyzed. Results: The median age of the patients was 34.5 years. The most common presentation was unilateral painless testicular mass (87.5%). Seminoma represented 53% of cases and almost half of them had Stage I disease. For all patients, the clinical stage and International Germ Cell Cancer Collaborative Group (IGCCC) risk classification were significantly associated with survival outcomes. Five-year overall survival for stage I patients was 100%, compared to 87.5% for stage II (p<0.0001). Patients with good risk had a 5-year OS of 87.4% while none of the poor risk group survived for 5 years (p =0.002). The 5-year disease-free survival for stage I was 83% for those who remained under active surveillance versus 87.5% for those who received adjuvant carboplatin (p=0.364). Conclusions: Stage I TGCTs has an excellent overall survival regardless of the treatment modality received. In advanced disease, the clinical stage and IGCCC risk stratification remain valid prognostic risk factors.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
影响睾丸生殖细胞肿瘤应答率和生存率的因素:埃及单一机构的经验
背景:睾丸生殖细胞肿瘤(TGCT)是青年男性最常见的癌症,也是最可治愈的实体瘤之一。不同阶段的治疗方式因中心而异。目的:描述埃及癌症中心TGCT的管理及其结果。方法:回顾性分析2012年1月至2016年12月期间接受TGCT治疗的患者的病历。包括32名患者。对人口统计学、临床、治疗和结果数据进行分析。结果:患者的中位年龄为34.5岁。最常见的表现是单侧无痛性睾丸肿块(87.5%),占53%的病例为精原细胞瘤,其中近一半为I期疾病。对于所有患者,临床分期和国际癌症生殖细胞合作小组(IGCC)风险分类与生存结果显著相关。I期患者的5年总生存率为100%,与II期的87.5%相比(p<0.0001)。高危患者的5年OS为87.4%,而低危组无一存活5年(p=0.002)。仍在积极监测下的患者I期的5年无病生存率为83%,而接受卡铂辅助治疗的患者为87.5%(p=0.364)。结论:I期TGCT具有良好的总生存率而不管所接受的治疗方式如何。在晚期疾病中,临床分期和IGCC风险分层仍然是有效的预后风险因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
12
审稿时长
8 weeks
期刊最新文献
The Impact of Trastuzumab Administration Patterns on the Long-Term Clinical Outcomes of Patients with Non-Metastatic Breast Cancer in a Resource-Limited Setting Chordoid Meningioma with Extensive Lymphocytic Infiltration Forming Lymphoid Follicles: A Case Report Clinical Trials on Colorectal Cancer in South Africa The Influence of Serum Leptin Level and Body Mass Index on the Prognosis of Patients with Diffuse Large B Cell Lymphoma Multicentric vs. Unresectable Unicentric Castleman Disease with Active Presentation: An Orphan Rare Disease in a Young Egyptian Female Patient. A Case Report
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1